Merck To Present First-Time Results From Three Pivotal Clinical Trials At ESMO Congress; Data Demonstrate Improvements In Recurrence-Free Survival And Distant Metastasis-Free Survival Versus KEYTRUDA Alone In Patients With Completely Resected Stage IIB-IV Melanoma

뉴스 본문을 불러오고 있어요.

Merck To Present First-Time Results From Three Pivotal Clinical Trials At ESMO Congress; Data Demonstrate Improvements In Recurrence-Free Survival And Distant Metastasis-Free Survival Versus KEYTRUDA Alone In Patients With Completely Resected Stage IIB-IV Melanoma | 웨이프 WAPE

Merck To Present First-Time Results From Three Pivotal Clinical Trials At ESMO Congress; Data Demonstrate Improvements In Recurrence-Free Survival And Distant Metastasis-Free Survival Versus KEYTRUDA Alone In Patients With Completely Resected Stage IIB-IV Melanoma

기사 요약

관련 종목

댓글 —